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105AD7 is a human monoclonal antibody that mimics the complement regulatory protein, CD55, overexpressed by many solid
tumours including osteosarcoma. This study was designed to assess the toxicity and efficacy of this vaccine in a young age group of
patients within 1–6 months of myleosuppressive chemotherapy. Out of 28, 20 (71%, 95% CI 51–87%) patients showed a significant
T-cell proliferation response in vitro to the 105AD7 protein but not to human IgG. Furthermore, 13 out of 22 (59%, 95% CI 36–79%)
patients showed antigen-specific gIFN secretion (range 20–370U/ml). Nine out of 28 (32%, 95% CI 16–52%) patients made weak
antibody responses to CD55. This study showed that 105AD7 was well tolerated in younger patients with osteosarcoma. In addition,
two patients with possible clinical responses were given compassionate permission to continue immunisation quarterly for 2 years.
They both remain alive and disease free 5.8 and 6.5 years from original diagnosis of osteosarcoma and showed no adverse effects of
repeated immunisation. In conclusion, the majority of patients showed measurable T helper responses when vaccination was
commenced within a 6-month window of intensive chemotherapy with no clinically significant toxicity. Future clinical trials
incorporating immune stimulation strategies should include early introduction of vaccines during the highest risk period for relapse.
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Osteosarcoma is a high-grade bone tumour that affects mainly
adolescents and young adults. Two-thirds of patients diagnosed
before the age of 30years have a localised primary tumour in a
limb bone. Of these, about 50–60% can expect to be long-term
disease-free survivors with modern therapies that include intensive
multiagent chemotherapy and surgical resection (Souhami et al,
1997; Fuchs et al, 1998). The remaining one-third of patients with
osteosarcoma have a poorer prognosis and present with either a
primary in the axial skeleton or metastatic disease. Even among
localised disease, most relapses occur within 2 years of initial
diagnosis, and a third of patients relapse or die within 6 months of
the scheduled end of multiagent chemotherapy. Comparisons of
the several national and international clinical trials of manipula-
tion of chemotherapy type and dose intensity suggest a limited role
for conventional chemotherapy in further improvements in disease
control. Hence, there is a need to search for novel approaches.
A possible therapeutic role for immunomodulation in osteo-
sarcoma was suggested by the naturally occurring dog model of
this disease, in which injections of the macrophage activator,
liposomal encapsulated muramyl tripeptide phosphatidyl ethano-
lamine (MTP-PE) induced regression. The role of MTP-PE as an
immune stimulatory adjuvant therapy was tested in a recent trial
conducted by the Children’s Oncology Group in North America.
This 2 2 factorial trial randomised patients to receive control
chemotherapy (methotrexate, doxorubicin and cisplatin) with or
without the addition of ifosfamide and with or without MTP-PE.
Preliminary results of this trial have indicated that although
neither treatment offers an event-free survival benefit individually,
there is a synergistic effect when ifosfamide and MTP-PE are
administered together (Meyers et al, 2001) Although suggestive,
this study does not provide conclusive evidence of the benefit from
this form of immunomodulation.
In order to impact on the early relapses, any immunotherapy
approach would have to be commenced relatively early in the course
of treatment. Since the chemotherapy given for osteosarcoma is
very myelosuppressive, we wished to test whether patients could
mount an immune response to a relevant tumour antigen if a
vaccination strategy was commenced within 1–6 months of
completion of chemotherapy. We chose to use an anti-idiotypic
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smonoclonal antibody, 105AD7, whose safety had been demon-
strated in two previous trials in patients with colorectal cancer.
105AD7 is a human anti-idiotypic monoclonal antibody that was
cloned from a cancer patient who had received the radiolabelled
mouse monoclonal 791T/36 for diagnostic imaging (Austin et al,
1989). 791T/36 was subsequently shown to recognise CD55, a
complement regulatory protein overexpressed by tumours to
protect them from complement attack. 105AD7 was shown to have
both amino acid and structural homology with CD55 and could
therefore be used as a vaccine to induce antitumour immune
responses (Spendlove et al, 2000).
In a phase I clinical trial in metastatic colorectal cancer patients,
105AD7 induced antitumour inflammatory responses with no
associated toxicity (Denton et al, 1994). However, in a subsequent
double-blind randomised phase II trial there was no survival
benefit in the setting of measurable disease (Maxwell-Armstrong
et al, 2001). This may have been due to the immunosuppressive
effects of large tumour burden as a neoadjuvant trial showed
promising results indicating a valuable immune response (Durrant
et al, 2000a,b; Schwann et al, 2000). As 791T/36 was originally
raised against a human osteogenic tumour cell line and was used
successfully to image osteosarcomas in vivo (Farrands et al, 1983),
we proposed that 105AD7 may be a suitable vaccine for treatment
of this disease. Previous experience with colorectal cancer
suggested that 105AD7 would be most effective in treatment of
patients with minimal residual disease.
This study had two main aims: to assess the toxicity of
vaccinating osteosarcoma patients with 105AD7 and to determine
the ability of these patients to raise an immune response to
this vaccine.
MATERIALS AND METHODS
Patients
Patients were recruited from four centres in England (The
Middlesex Hospital, London; Royal Marsden Hospital, Sutton,
Royal Victoria Infirmary, Newcastle and St James Hospital, Leeds).
Eligible patients had a diagnosis of high-grade osteosarcoma, were
aged o30years at time of study entry and had a lymphocyte count
of 40.5 10
9ml
 1, and biochemical indices of renal and liver
function within three times the age-related upper limit of normal.
Patients were recruited if they were deemed at high risk of
treatment failure because they had presented with metastatic
disease, had experienced at least one relapse or if they presented
with a localised limb primary tumour and who were not
participating in another clinical trial. Patients who generally have
a better outlook were included in this phase I/II study due to the
good safety profile of the vaccine in previous studies in adult
colorectal cancer patients. All patients had to have completed
current best standard therapy for their situation and to have
received their last dose of chemotherapy within the previous 1–6
months. All patients had a Lansky performance score of 480 or a
Karnofsky performance score of 460%, according to age.
Exclusion criteria were any autoimmune disease, lymphocyte
count o0.5 10
9l
 1, platelet count 50 10
9l
 1, concomitant
anticancer treatment or other vaccinations within the previous 3
weeks. All patients (and their parents when the patient was aged
less than 16 years) gave fully informed, written consent to
participate in the study.
Patients were required to have baseline imaging studies,
appropriate to their clinical situation and follow-up, immediately
prior to study entry, to confirm either clinical remission or
presence of disease. Patients with measurable disease were
required to have the appropriate imaging modality repeated at
week 9, to look for response, and again at week 14, to assess
durability of response.
Vaccination schedule and venous blood sample handling
The vaccination schedule and blood sampling are shown in
Figure 1. For isolation of lymphocytes, a 20ml baseline venous
blood sample was taken in preservative-free heparin during the
week prior to commencement of vaccination and again at week 0,
3, 6, 9, 12 and 15. Full blood count, urea, electrolytes, creatinine
and liver function tests were performed at weeks 0, 3, 6 and 12 at
the clinical trial centre for that patient. Patients received an
intradermal (i.d.) injection of 10mg of 105AD7 and an intramus-
cular (i.m.) dose of 100mg of 105AD7 adsorbed on alyhdrogel 85 at
weeks 0, 3, 6 and 12, immediately following the blood sampling.
The venous blood samples were sent by overnight courier to the
immune analysis laboratory where lymphocytes were separated on
Lymphoprep (Flow Laboratories, Irvine, Scotland) and stored at
 1801C. Plasma was also stored at  801C.
This trial was carried out under the auspices of the Cancer
Research UK Drug Development Office with local ethical approval
in all centres. The study was carried out in accordance with the
Declaration of Helsinki 1996.
Antibody
Clinical grade 105AD7 human antibody was produced as described
previously using the guidelines of the Cancer Research Campaign,
United Kingdom (Denton et al, 1994). The trial supplies were
prepared under cGMP conditions. Antibody for immunisation was
prepared adsorbed on alhydrogel 85 (Superfos Biosector now
Brenntag Biosector A/S, Elsenbakken, Denmark) at 100mgml
 1 in
sterile, pyrogen-free phosphate-buffered saline in a 1ml type 1
glass ampoule containing 1ml. The weight ratio of 105AD7 to
alhydrogel 85 was 1:10. The skin test dose was prepared at
100mgml
 1 in sterile, pyrogen-free phosphate-buffered saline in a
1-ml type 1 glass ampoule containing 0.125ml. Stability studies
have shown that the antibody can be stored at 41C for a minimum
of 5 years with no loss in binding activity.
T-cell analysis
A complete set of cryopreserved lymphocytes for each patient was
defrosted for simultaneous analysis. A sample of peripheral blood
mononuclear cells (PBMCs) was removed, irradiated and used as
antigen-presenting cells. The remaining PBMCs were stimulated
with these antigen-presenting cells in the presence of 105AD7
(10mgml
 1) or control human IgG antibody (10mgml
 1) in RPMI
(Flow laboratories) containing 10% allogeneic human serum at
10
6cellml
 1 in 24-well plates. All cultures were incubated in a
humidified incubator of 5% CO2 and 95% air at 371C. Proliferation
of lymphocytes was quantified after 5 days by resuspending the
cells and removing four 100ml aliquots and incubating these cells
in fresh 96-well plates overnight in the presence of 3[H]thymidine.
All experiments were in quadruplicate and there was always an s.d.
of less than 10%. Each time course was repeated twice and if there
was any discordance it was repeated a third time. The response to
human IgG was not significantly different from the medium
control by a one-way analysis of variance. For clarity, results on
figures and tables are presented as a stimulation index
(SI)¼incorporated counts per minute (cpm) in the presence of
105AD7/cpm in the presence of Human IgG. One-way analysis of
variance showed that all samples that responded with a two-fold
increase in response to 105AD7 as compared to human IgG were
significant.
cIFN Secretion
gIFN secretion was analysed in tissue culture supernatant of
lymphocytes that had been stimulated with either 105AD7
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Figure 1 (A) Patients showing no proliferative response to 105AD7 or human IgG control. (B) Patients showing proliferative response to 105AD7 but
not human IgG control (no prevaccination response). (C) Patients showing proliferative response to 105AD7 but not human IgG control (with
prevaccination response). T-cell proliferation was assessed by
3H-labelled thymidine incorporation following 5-day stimulation with either 105AD7 or
control human IgG:
SI ¼
cpm105AD7
cpmhIgG
An SI of greater than 2 is considered significant. Arrows denote injection with 105AD7 by intrademal (10mg) and intramuscular (100mg on alum) injection.
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 1) or human IgG (10mgml
 1) for 5 days in vitro gIFN
was detected by ELISA (R&D, Abingdon, Oxon, UK).
Antibody response
CD55 and CEA were purified from 791Tcells and colorectal
tumours using previously described methods (Price et al, 1987;
Spendlove et al, 1999) and used to coat microtitre plates by
overnight incubation at room temperature. Plates were blocked
with phosphate buffer and saline (PBS) containing 1% bovine
serum albumin (BSA). Plasma samples were defrosted, diluted in
PBS containing 0.1% BSA and incubated with the antigens for 1h
at 41C. Bound antibodies were detected by rabbit anti-human
horseradish peroxidase (Dako, Denmark) and TMB substrate
(R and D). Absorbance was read at 402mm on a plate reader.
HLA typing
Patients MHC class II phenotyping was measured by standard
molecular techniques.
Statistical methodology
Due to the small number of patients available to the study and the
fact that this vaccine had not previously been tested in
osteosarcoma, the sample size was determined using the single
stage procedure proposed by Fleming (1982). This method makes
use of the response probabilities of interest, and allows statistically
meaningful designs to be constructed with relatively small patient
numbers. Sample sizes for Fleming’s single stage procedure are
tabulated by A’Hern (2001). The lowest response probability of
interest is set as 0.50 and the highest is set as 0.75. To reliably
evaluate the immunological response rate for the new vaccine
(significance level¼5%, power¼80%), 23 patients would have to
be entered into the study.
Statistical analysis was carried out using SPSS Version 1 for
Windows. Exact 95% confidence intervals (CI) for response rates
were obtained from Geigy Scientific Tables (Altman et al, 2000).
RESULTS
This trial had two main aims. The phase I component was to assess
the toxicity profile of this agent in children and young adults, since
the previous excellent safety profile had been documented only in
older adults with colorectal cancer. The phase II component
addressed the question of whether 105AD7 was capable of
stimulating a specific immune response in this relatively heavily
pretreated group of patients within 1–6 months of their last dose
of chemotherapy. The evaluation of any clinical responses where
possible was as a secondary end point
In total, 31 patients were recruited to the study from August
1998 to January 2001. One withdrew prior to receiving any vaccine
as a baseline CT scan showed recurrent disease. Two further
patients withdrew after one or two doses of vaccine due to early
progressive disease. The remaining 28 patients received three (5)
or four (23) doses of vaccine. In total, 30 patients were evaluated
for toxicity, having received at least one dose of vaccine, and 28
had received at least three doses of vaccine to give sufficient time
points of blood sampling for analysis of immune response.
Immune responses
The immune response of patients to the anti-idiotypic vaccine was
assayed by in vitro T-cell proliferation responses following
exposure to 105AD7 and to control human IgG. In a subset of
patients, stimulation of secretion of gIFN following the same
stimulator was also measured. Overall 20 out of 28 (71%, 95% CI
51–87%) patients showed a proliferative response to 105AD7 but
not to human Ig. Patients’ proliferation responses are summarised
in Table 1. Patients PBMC proliferative responses could be divided
into three groups: Group I (eight patients) failed to show any
significant proliferation response to 105AD7 postvaccination
(Figure 1A). Group II (seven patients) showed lymphocyte
proliferation in response to the vaccine but had no pre-existing
response to 105AD7 (Figure 1B). Group III (13 patients) showed a
pre-existing response to 105AD7, which was subsequently boosted
by the vaccine (Figure 1C). Response data for all three groups are
summarised in Table 1 and Figure 1.
In contrast to previous studies in chemonaı ¨ve colorectal cancer
patients who responded to the first vaccination, a median of three
doses of vaccine were required to observe a peak PBMC proli-
ferative response in this group of patients with osteaosarcoma. A
similar delayed response was observed in the group of patients
who had evidence for a pre-existing response to 105AD7.
Table 1 Immune responses of patients
Proliferation
(SI)
Patient
HLA/DR
type Pre Post
Number of
injections to
observe response
cIFN
(Uml
 1)
Group I – Patients who failed to show a proliferative response to 105AD7 or human Ig
3 1, 3 1.3 1.6 — 0
6 13, 15 0.9 1.3 — ND
12 1, 7 0.9 1.1 — ND
21 13, 15 0.9 1.8 — 0
22
b 11, 13 2.1 1.4 — 60
24
b 4, 8 1.4 1.6 — 300
26 1, 7 1.5 1.1 — 0
28 7, 12 1.3 1.9 — 370
Group II – Patients who showed a proliferative response to 105AD7 but not human Ig
20 7, 11 0.9 4.0 1 370
9
a 4, 11 1.1 6.9 2 45
23 1, 7 1.1 3.1 2 0
31 ND 1.3 8.0 2 25
7  17 1.3 19.6 4 0
16 4, 17 1.3 6.6 4 70
17 7, 17 1.1 2.1 4 ND
Group III – Patients who had a pretreatment response to 105AD7 and who also
showed a proliferative response to 105AD7 but not to human Ig
18
b 12, 7 5.6 5.9 1 130
14 1, 4 3.9 6.4 2 0
15
b 3, 4 2.4 6.2 2 ND
1
a 1, 7 8.8 12.6 3 90
2 3, 7 6.4 7.4 3 185
8 1, 15 6.7 3.9 3 ND
10 1, 3 2.2 12.7 3 ND
27
b 4, 13 8.5 19.9 3 60
5  15 2.3 4.5 4 20
11 4, 13 9.6 4.6 4 0
13  3 4.0 2.0 4 40
29 10, 17 2.0 2.0 4 0
4 2.5 7.5 1 0
aPatients received four doses of 105AD7 and compassionate immunisation quarterly
for 2 years.
bOnly three doses due to progressive disease.
cPatients were phenotyped
for MHC class II using standard molecular techniques.
dProliferation was assessed by
3H-labelled thymidine incorporation following 5-day stimulation with either 105AD7
or control human IgG.
eSI¼cpm 105AD7/cpm hIgG.
fSecretion of gIFN was assessed
by sandwich ELISA (R&D Systems) following 5-day stimulation with 105AD7 or
control human IgG. Only a few samples showed gIFN secretion in response to human
IgG and these values were considered background and were subtracted from the
levels induced by 105AD7 stimulation.
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sPrevious studies have shown a correlation between response to
105AD7 and an expression of HLA-DR 1, 3, 7 phenotypes. Similar
results were observed in this study with 11 out of 15 (73%) of
patients expressing these phenotypes showing a proliferation
response. However, this study suggests that patients expressing
HLA-DR 13, 15 and 17 haplotypes may also respond to 105AD7
vaccine (Table 1).
In total, 22 patients were also assayed for secretion of gIFN. A
total of 13 patients (59%, 95% CI 36–79%) secreted gIFN in
response to 105AD7 but not to pooled human immunoglobulin.
There was a correlation between the proliferation assay and gIFN
secretion in 10 patients. Six patients showed a proliferation
response but no significant secretion of gIFN could be observed.
Three patients showed gIFN secretion to 105AD7 but failed to have
a significant proliferation response. Three patients failed to
respond in either assay.
Patients were also screened for their ability to make an antibody
response. The antigen 105AD7 mimics is CD55. At a dilution of
1/3, 11 out of 28 patients showed a boosted antibody response to
CD55 that was greater than the response to CEA (carcinoem-
bryonic antigen; Figure 2). A further six patients had a pre-existing
response to CD55 that was not boosted by vaccination with
105AD7. All but one of these patients was in group III that also
showed a pre-existing PBMC proliferative response to 105AD7
(data not shown). Of the nine patients showing an anti-CD55
response only five of these were titratable and two were IgM and
three IgG responses.
Toxicity
Of the 30 patients assessed for toxicity, 15 patients had a minor
adverse event (grade 1 or 2) that was deemed probably or almost
certainly related to administration of 105AD7. These events
comprised 33 episodes of local symptoms at the injection site,
lasting up to 24h, and three episodes of intermittent chest pain in
one patient and general lethargy in one other.
Two patients experienced exacerbation of tumour-related pain
in the week following vaccination, one requiring hospitalisation for
intravenous opiates. However, both of these patients had extensive
disease at time of study entry, had experienced similar unstable
pain prior to study entry and both had subsequent early
progressive disease. One patient developed grade 3 lymphopaenia
that resolved spontaneously after the second dose of vaccine and
did not recur.
Two patients were given prolonged vaccination on compassio-
nate grounds, as there was a possibility that they had had a benefit
from the vaccine. They each continued both i.d. and i.m.
vaccination on a 2–3 monthly basis until they were 2 years from
the initial vaccination. Neither patient experienced any vaccine-
related symptoms. This lack of toxicity is in keeping with previous
clinical studies in colorectal cancer patients (Denton et al, 1994;
Durrant et al, 2000a; Maxwell-Armstrong et al, 2001).
Disease response
This study was not designed to test antitumour efficacy. Only five
patients entered the study with measurable disease (Table 2).
Three patients (CRC15, 22, 24) received only three doses of vaccine
due to early disease progression, one patient (CRC7) completed all
four doses as sole therapy for an early local recurrence of a pelvic
primary tumour but progressed again shortly afterwards. The fifth
patient (CRC9) showed evidence of possible response and remains
well, as described below.
Table 2 shows the status at study entry and clinical course of all
the patients in the trial, grouped according to their in vitro
immune response to 105AD7. There were no obvious differences
between the three immune response groups in either number of
prior relapses, number with measurable disease, clinical risk group
or median interval from end of last chemotherapy to study entry
(18.5, 21 and 18 weeks for groups I, II and III respectively). In
patients who failed to mount an immune response (group I)
after 105AD7 vaccination, all those who showed evidence of
disease subsequently died of disease. However, in those patients
who demonstrated an immune response (Group II and III),
there were five patients who remain alive and disease free (n¼3, at
32, 49, 61 months from study entry) or alive with disease (n¼2
at 34 and 50 months from study entry) although they showed
evidence of disease.
Two patients showed unusual clinical courses CRC9 and CRC1.
One CRC9 in response group II had presented 12 months prior to
study entry with a pelvic primary and lung metastases that showed
no response to conventional first line chemotherapy. She was
therefore treated with an experimental approach combining high-
dose chemotherapy and stem cell rescue with systemic intravenous
radioactive samarium. Following completion of this, she was
found to have residual inoperable lung metastases. As she had
shown in vitro responses to 105AD7 (Figure 3A), she was
allowed to continue on a compassionate basis with what was
believed to be the best potential therapeutic vaccine schedule.
CRC9 received a total of a further six doses of vaccine at 3 monthly
intervals. Her in vitro immune response fell dramatically after the
end of the formal study, suggesting that a memory response was
not being established (Figure 3A). However, with resumption of
vaccination this was rapidly boosted and reached a peak
stimulation index of 32. Although this then fell to within
the unmeasurable range on a single sample taken after completion
of the prolonged vaccination, she remains free of signs of
progressive disease 4.2years from study entry and 2.2years from
her last dose of vaccine.
The second patient (CRC1) was in response group III. She had
originally been treated for localised distal femoral osteosarcoma
and had entered onto the 105AD7 study 21 weeks after completion
of chemotherapy with cisplatin, doxorubicin and high-dose
methotrexate. A routine follow-up chest radiograph performed at
week 6 of the vaccine study (and 1 year from original diagnosis)
had shown appearance of a single solitary 0.5cm nodule,
CD55 ELISA on trial patient plasma
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Figure 2 Antibody responses of patients to CD55 and control antigen
CEA, pre- and postimmunisation with 105AD7. Antibodies were detected
in patients serum by ELISA.
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in the interval prior to excision of this nodule for diagnostic
purposes, during which time the nodule decreased slightly on chest
X-ray. At surgery, both this and a second, 2mm nodule found in
the other lung were excised completely and found to contain viable
osteosarcoma. Despite the early relapse, the patient declined
second line chemotherapy but was granted permission to continue
a prolonged course of vaccination at 2 monthly intervals over a
2-year period. Immune response data (Figure 3B) showed a
decrease in a pre-existing endogenous response, which was
boosted after the third dose of vaccine. It is of note that at this
timepoint the patients pulmonary metastasis stabilised. On
continued vaccination, her in vitro immune response remained
measurable except for a single sample at week 63. The patient
remains free of recurrence 5.2years from study entry and 3.2years
from last vaccination.
DISCUSSION
105AD7 is a human anti-idiotypic antibody that binds to the
monoclonal antibody 791T/36 and mimics the complement
regulatory protein CD55. It has previously been shown to induce
antitumour inflammatory responses that are associated with
tumour cell apoptosis in colorectal cancer patients. As 791T/36
has been shown to stain osteosarcoma tumours and when
radiolabelled has been used successfully in diagnostic imaging of
these tumours. Therefore, osteosarcoma patients were potential
candidates for 105AD7 vaccination. Colorectal cancer patients with
minimal residual disease were shown to have better immune
responses to 105AD7 than either patients with recurrent disease or
patients with a large tumour burden (Durrant et al, 2000a;
Maxwell-Armstrong et al, 2001). This may have been due to the
immunosuppressive effect of a large tumour burden. The
objectives of this study were therefore to assess the immune
response to 105AD7 of children and young adults (o30 years of
age) when commenced within 1–6 months of finishing systemic
chemotherapy. Its main end points were toxicity and immune
response, with evaluation of any clinical responses as a secondary
end point.
There was no clinically significant toxicity associated with the
vaccination even in the two patients who were given compassio-
nate permission to continue being immunised for a 2-year period.
This is in accord with the lack of significant toxicity seen in the
colorectal cancer studies in older patients. 105AD7 combined i.d.
and i.m. vaccine has now been administered safely to over 200
cancer patients across a wide age range.
The majority of patients (71%) showed an in vitro T-cell
proliferation response to 105AD7 but not to the control human
IgG. However, three immunisations were required to induce peak
proliferative responses in the majority of patients. This is in
contrast to the chemonaive colorectal cancer patients, who showed
peak proliferation following their initial vaccination with 105AD7.
Previous studies have shown that patients with an HLA-DR 1, 3 or
7 phenotype responded to 105AD7 vaccination. This observation
was confirmed in this study with 80% of patients with these
haplotypes showing a proliferation response to 105AD7. However,
patients with a DR 13, 15 or 17 phenotype also responded
suggesting that these haplotypes may also be able to present the
class II peptide. This is not uncommon as many class II haplotypes
Table 2 Clinical responses of patients
Trial
number
Clinical
risk
group
Interval from
last chemo to
vaccination
Immune
response
group
No. of
prior
relapses
Disease at study
entry Subsequent course
Current
status
FU
a
(m)
Date of
last FU
info
3 1 24 I 0 NMD Never relapsed ADF 45 09/04/02
21 1 16 I 2 NMD Never relapsed ADF 34 11/11/2000
26 1 21 I 0 NMD Never relapsed ADF 28 27/12/2001
28 2 25 I 0 NMD Never relapsed ADF 24 03/02/2003
6 1 14 I 2 NMD Nodal and bone relapse DOD 18 18/10/2001
12 1 12 I 0 NMD Two further relapses DOD 26 17/10/2000
22 1 22 I 2 Equivocal PD in lungs
on CT
PD lungs DOD 18 04/12/2002
24 1 12 I 3 Macroscopic residue Local recurrence and lung mets DOD 4 25/11/2002
9 1 22 II 0 Residual inoperable
primary & metastatic
disease
No further progressions ADF 49 06/10/2003
17 1 22 II 1 NMD No further relapse ADF 33 26/06/2003
23 2 25 II 0 NMD Never relapsed ADF 31 20/07/2001
20 1 21 II 2 NMD PD lungs AWD 34 17/10/2002
7 1 20 II 1 Local recurrence Local PD DOD 6 27/01/2003
16 2 14 II 0 NMD Two further relapses (lung and abdo) DOD 19 20/11/2002
31 1 12 II 2 NMD One further relapse DOD 8 02/10/2001
1 2 21 III 0 NMD pulm mets during vaccination ADF 61 26/10/2003
5 1 27 III 1 NMD No further relapse ADF 45 02/01/03
10 1 25 III 1 NMD Two skin relapses in thoracotomy scar ADF 32 17/02/2000
11 2 8 III 0 NMD Never relapsed ADF 44 01/01/2003
29 2 18 III 0 NMD Never relapsed ADF 26 12/09/2001
2 1 19 III 3 NMD Relapsed, Feb 2002 AWD 50 20/06/2002
4 1 11 III 2 NMD Further pulm relapse DOD 10 26/06/2003
8 1 11 III 0 NMD Three further relapses DOD 25 13/11/2002
13 1 9 III 1 NMD One further relapse DOD 36 24/05/2001
14 1 7 III 1 NMD Further pulm relapse DOD 17 13/02/2000
15 1 22 III 4 PD Continued PD DOD 2 22/06/2001
18 1 9 III 1 NMD Local recurrence, then mediastinal
recurrence, further local recurrence
DOD 16 07/07/2001
27 1 23 III 2 NMD Pulmonary relapse DOD 7 04/02/2003
NMD¼no measurable disease; PD¼progressive disease.
aFU is months from study entry.
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shave similar anchor residue requirements and show promiscuous
binding of class II peptides (Chicz et al, 1993).
Lymphocytes responding to 105AD7 also secreted gIFN
suggesting that 105AD7 is inducing a Th1 immune response. This
is in agreement with the low levels of anti-CD55 antibodies
induced by this vaccine, suggesting that low-dose immunisation
with 105AD7 predominantly induces a cellular Th1 rather than a
Th2 response. This is in agreement with our animal studies that
showed low doses of 105AD7 induced DTH responses whereas
higher doses in combination with complete Freund’s adjuvant
induced anti-CD55 antibody responses (Austin et al, 1991).
Several patients had an apparent pre-existing proliferation
response to 105AD7 prior to vaccination. In a recent randomised
study in colorectal cancer, many of the unimmunised control
patients showed an in vitro response to 105AD7 (unpublished
results). An alternative suggestion is that disease regression
associated with intensive chemotherapy induces an immune
response to CD55 that can be detected in vitro with 105AD7. In
this context six out of eight patients in group III also had an
antibody response to CD55 prior to vaccination. High levels of
CD55 released from dying osteosarcoma tumours presented in the
context of inflammation may overcome immune ignorance or
tolerance associated with this self-antigen. Further studies using
antigen-specific ELISPOT assays will determine the frequency and
specificity of these T-cell responses.
This trial was not designed to measure significant clinical
benefit and only five patients with measurable disease were
enrolled. However, disease status was followed in all patients pre-
and postvaccination. Two patients showed evidence of clinical
responses. One patient, who entered the study without measurable
disease, had early lung metastasis, occurring within 1 year of
original diagnosis, which was suspected during immunisation. She
continued the vaccine on a compassionate basis for a total of 2
years without any other therapy. This patient remains disease free
4.7 years from time of metastasis. The second patient had
chemorefractory primary disease that stabilised on 105AD7
immunisation. Immunisation was continued for a further 2 years
and their disease has remained stable for a further 2 years since
completion of vaccinations.
A theoretical concern in the design of this study was that
the intensive chemotherapy used to treat osteosarcoma might
prevent the mounting of a significant immune response when
vaccination is commenced within a time frame of 6 months
following end of chemotherapy, when patients are still considered
immunosuppressed. This study demonstrates that this did not
prevent this young group of patients responding to vaccination
with 105AD7.
In conclusion, this study showed that 71% of young osteosarco-
ma patients were capable of mounting an immune response to an
anti-idiotypic vaccine approach with 105AD7, commenced within
a short time frame (6 months) of completion of intensive
chemotherapy. There was no clinically significant toxicity asso-
ciated with the vaccine. These results suggest that future trials of
immunotherapy in osteosarcoma could include a vaccination
strategy implemented early, when patients destined to relapse still
have minimal disease burden. A randomised phase III study, with
progression-free survival as an end point, is necessary to
determine if this approach confers any survival benefit in
osteosarcoma.
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